SI20361A - Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji - Google Patents

Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji Download PDF

Info

Publication number
SI20361A
SI20361A SI200000107A SI200000107A SI20361A SI 20361 A SI20361 A SI 20361A SI 200000107 A SI200000107 A SI 200000107A SI 200000107 A SI200000107 A SI 200000107A SI 20361 A SI20361 A SI 20361A
Authority
SI
Slovenia
Prior art keywords
pde5 inhibitor
pde5
treatment
selective
inhibition
Prior art date
Application number
SI200000107A
Other languages
English (en)
Slovenian (sl)
Inventor
Jefrey Thomas EMMICK
Kenneth Michael Bv Ferguson
William Ernest Pullman
John Steven Whitaker
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI20361(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of SI20361A publication Critical patent/SI20361A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Glass Compositions (AREA)
SI200000107A 1999-04-30 2000-04-26 Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji SI20361A (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30

Publications (1)

Publication Number Publication Date
SI20361A true SI20361A (sl) 2001-04-30

Family

ID=22452153

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200000107A SI20361A (sl) 1999-04-30 2000-04-26 Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji
SI200030225T SI1173181T1 (en) 1999-04-30 2000-04-26 Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200030225T SI1173181T1 (en) 1999-04-30 2000-04-26 Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Country Status (47)

Country Link
EP (2) EP1415652A3 (cs)
JP (2) JP4975214B2 (cs)
KR (2) KR100577057B1 (cs)
CN (2) CN1196487C (cs)
AT (1) ATE251908T1 (cs)
AU (3) AU3012900A (cs)
BE (1) BE1012957A5 (cs)
BR (2) BR0003046A (cs)
CA (2) CA2371684C (cs)
CH (2) CH1173181H1 (cs)
CO (1) CO5170493A1 (cs)
CZ (1) CZ296534B6 (cs)
DE (3) DE10021266A1 (cs)
DK (2) DK1173181T6 (cs)
DZ (1) DZ3171A1 (cs)
EA (2) EA005416B1 (cs)
ES (2) ES2187234A1 (cs)
FI (1) FI20000976L (cs)
FR (1) FR2795646B1 (cs)
GB (1) GB2351663A (cs)
GR (1) GR1003575B (cs)
HK (1) HK1041204B (cs)
HR (2) HRP20000243A2 (cs)
HU (2) HUP0001632A3 (cs)
ID (1) ID25704A (cs)
IE (1) IE20000315A1 (cs)
IL (3) IL135817A0 (cs)
IT (1) ITMI20000922A1 (cs)
LT (1) LT4758B (cs)
LU (1) LU90569B1 (cs)
LV (1) LV12560B (cs)
MX (2) MXPA00003997A (cs)
NL (1) NL1015027C2 (cs)
NO (2) NO20002097L (cs)
NZ (2) NZ514882A (cs)
PE (1) PE20010071A1 (cs)
PL (2) PL197813B1 (cs)
PT (2) PT1173181E (cs)
SE (1) SE0001518L (cs)
SG (1) SG98384A1 (cs)
SI (2) SI20361A (cs)
SK (1) SK285415B6 (cs)
SV (1) SV2002000055A (cs)
TR (1) TR200001132A2 (cs)
UA (1) UA72248C2 (cs)
WO (1) WO2000066099A2 (cs)
ZA (2) ZA200002058B (cs)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003505509A (ja) * 1999-08-03 2003-02-12 リリー アイコス リミテッド ライアビリティ カンパニー β−カルボリン製薬組成物
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289990A1 (en) * 2000-06-08 2003-03-12 Lilly Icos LLC Tetracyclic diketopierazine compounds as pdev inhibitors
MXPA03000887A (es) * 2000-08-02 2004-04-05 Lilly Icos Llc Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
CA2445620C (en) * 2001-06-05 2008-07-08 Lilly Icos Llc Tetracyclic compounds as pde5-inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
MX2008012495A (es) * 2006-03-28 2009-01-07 Javelin Pharmaceuticals Inc Formulaciones de dosis baja de diclofenaco y beta-ciclodextrina.
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
CA3091597A1 (en) * 2018-02-07 2019-08-15 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
WO1997043287A1 (en) 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
CZ299633B6 (cs) * 1997-04-25 2008-09-24 Pfizer Inc. Pyrazolopyrimidinony, meziprodukty pro jejich výrobu a farmaceutické a veterinární kompozice na jejich bázi
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
WO2000015639A1 (en) 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6743443B1 (en) * 1998-10-05 2004-06-01 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
EP1161255A4 (en) * 1999-03-08 2002-07-17 Merck & Co Inc METHOD AND MEANS FOR TREATING ERECTILE DYSFUNCTION
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
WO2000066114A1 (en) * 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
DE60005940D1 (de) 2003-11-20
SG98384A1 (en) 2003-09-19
DE60005940T3 (de) 2015-08-27
PE20010071A1 (es) 2001-03-22
PT102457A (pt) 2000-11-30
HUP0200912A3 (en) 2003-07-28
LV12560B (en) 2001-04-20
CA2371684A1 (en) 2000-11-09
KR20010020779A (ko) 2001-03-15
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
UA72248C2 (en) 2005-02-15
EP1173181A2 (en) 2002-01-23
NO20015275D0 (no) 2001-10-29
BR0003046A (pt) 2002-07-23
HUP0001632A2 (hu) 2001-05-28
HRP20010778B1 (en) 2005-04-30
NO322013B3 (no) 2017-11-06
HUP0001632A3 (en) 2001-12-28
IE20000315A1 (en) 2001-03-07
SV2002000055A (es) 2002-07-03
JP2000336043A (ja) 2000-12-05
FI20000976A0 (fi) 2000-04-26
DK1173181T6 (en) 2015-04-27
ID25704A (id) 2000-11-02
SE0001518D0 (sv) 2000-04-26
DK200000677A (da) 2000-10-31
AU769946C (en) 2005-01-13
DZ3171A1 (cs) 2000-11-09
EP1173181B1 (en) 2003-10-15
JP2002543116A (ja) 2002-12-17
GR20000100153A (el) 2000-12-29
IL146098A (en) 2007-06-03
SK15632001A3 (sk) 2002-02-05
HU0200912D0 (en) 2002-04-29
AU2004201988A1 (en) 2004-06-10
ATE251908T1 (de) 2003-11-15
AU4490800A (en) 2000-11-17
CA2371684C (en) 2007-10-23
FI20000976A7 (fi) 2000-10-30
PL197813B1 (pl) 2008-04-30
BE1012957A5 (fr) 2001-06-05
MXPA00003997A (es) 2002-03-08
GB0010199D0 (en) 2000-06-14
FR2795646B1 (fr) 2002-08-16
HK1041204B (en) 2004-03-05
NZ514882A (en) 2003-08-29
PL352629A1 (en) 2003-08-25
BR0010181A (pt) 2003-02-25
CA2307101A1 (en) 2000-10-30
CH692478A5 (de) 2002-07-15
EP1415652A3 (en) 2004-05-12
HU230369B1 (hu) 2016-03-29
TR200001132A3 (tr) 2001-01-22
HUP0200912A2 (en) 2002-08-28
ITMI20000922A0 (it) 2000-04-26
CA2307101C (en) 2003-01-28
EP1415652A2 (en) 2004-05-06
EA200000355A2 (ru) 2000-10-30
CN1196487C (zh) 2005-04-13
NO322013B1 (no) 2006-08-07
PT1173181E (pt) 2004-02-27
ZA200002058B (en) 2000-11-02
EA200101008A1 (ru) 2002-04-25
DE10021266A1 (de) 2000-11-16
NO20015275L (no) 2001-12-06
AU3012900A (en) 2000-11-02
GB2351663A (en) 2001-01-10
GR1003575B (el) 2001-05-14
ITMI20000922A1 (it) 2001-10-26
FR2795646A1 (fr) 2001-01-05
EA200000355A3 (ru) 2001-02-26
DK1173181T3 (da) 2004-02-16
AU769946B2 (en) 2004-02-12
EP1173181B3 (en) 2015-03-25
LU90569B1 (fr) 2002-02-27
CO5170493A1 (es) 2002-06-27
MXPA01010837A (es) 2002-11-07
NO20002097D0 (no) 2000-04-25
CZ20013879A3 (cs) 2002-04-17
NL1015027C2 (nl) 2001-02-14
IL146098A0 (en) 2002-07-25
NZ504163A (en) 2001-11-30
JP4975214B2 (ja) 2012-07-11
DE20007861U1 (de) 2000-08-24
ZA200108900B (en) 2003-03-26
CZ296534B6 (cs) 2006-04-12
DE60005940T2 (de) 2004-07-29
PL339897A1 (en) 2000-11-06
LT2000035A (lt) 2000-11-27
ES2208317T3 (es) 2004-06-16
LV12560A (en) 2000-11-20
CN1384746A (zh) 2002-12-11
KR100577057B1 (ko) 2006-05-10
HRP20000243A2 (en) 2001-12-31
SK285415B6 (sk) 2007-01-04
ES2208317T7 (es) 2015-09-15
SI1173181T1 (en) 2004-04-30
CN1292264A (zh) 2001-04-25
TR200001132A2 (tr) 2001-01-22
WO2000066099A2 (en) 2000-11-09
IL135817A0 (en) 2001-05-20
SE0001518L (sv) 2000-10-31
NO20002097L (no) 2001-10-26
LT4758B (lt) 2001-02-26
NL1015027A1 (nl) 2000-10-31
KR20020008396A (ko) 2002-01-30
EA005416B1 (ru) 2005-02-24
HU0001632D0 (en) 2000-06-28
CH1173181H1 (cs) 2019-07-15
ES2187234A1 (es) 2003-05-16
WO2000066099A3 (en) 2001-01-18
FI20000976L (fi) 2000-10-30

Similar Documents

Publication Publication Date Title
US6943166B1 (en) Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
SI20361A (sl) Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji
US6451807B1 (en) Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US20010053780A1 (en) Daily treatment for erectile dysfunction using a PDE5 inhibitor
CZ20001536A3 (cs) Orální léčivo
HK1065485A (en) Composition comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
KO00 Lapse of patent

Effective date: 20050216